Second quarter 2022 results

Second quarter 2022 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session.

(14:30 - 16:00 CET / 8:30am – 10am EST)

Featuring

Paul Hudson

Chief Executive Officer

Jean-Baptiste de Chatillon

Chief Financial Officer

Bill Sibold

Specialty Care

Olivier Charmeil

General Medicines

John Reed

R&D

Thomas Triomphe

Vaccines

Julie Van Ongevalle

Consumer Healthcare

Roy Papatheodorou

General Counsel

Highlights

Our performance in the second quarter was once again fueled by both higher sales across our key growth drivers and outstanding financial results. We remain ahead of schedule on our strategy and are confident in the outlook for the second half of the year.